This inventor holds 33 USPTO granted patents and 33 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: Autolus Limited, Immunoqure Ag, Ucl Business Plc. Active years: 2016-2026.
Location History:
- Bishop's Stortford, GB (2016 - 2021)
- London, GB (2018 - 2024)
Company Filing History:
28 out of 58 
5 out of 9 
2 out of 299 
Years Active: 2016-2026
Areas of Expertise:
Title: **Innovations and Achievements of Shimobi Onuoha**
Introduction
Shimobi Onuoha, an accomplished inventor based in London, GB, holds an impressive portfolio of 23 patents. His work primarily focuses on advancements in medical technology, particularly in the field of immunotherapy and genetic assessment.
Latest Patents
Among his latest contributions to the field, Onuoha has developed a patent entitled "Molecular Assessment of TRBC Usage." This invention describes a method for determining the T cell receptor β chain (TRBC) gene type of a cell by assessing the J gene type expressed in that cell, ultimately leading to a more accurate inference of the TRBC gene type. Additionally, it encompasses the use of CAR T cells targeted to specific TRBC types, which greatly enhances medical treatment modalities. Another significant patent is the "CD79-specific Chimeric Antigen Receptor," which involves a chimeric antigen receptor (CAR) that binds specifically to CD79. This invention also includes the relevant nucleic acid sequence and vector encoding the CAR, along with cells that express this CAR on their surface.
Career Highlights
Onuoha has had a notable career, during which he contributed to leading companies in the biotech sector. His experience includes working at Autolus Limited and UCL Business Plc, where he played a vital role in advancing innovative treatments and therapies based on his patented technologies.
Collaborations
Throughout his career, Onuoha has teamed up with several distinguished colleagues, including Shaun Cordoba and Simon Thomas. These collaborations have enabled him to foster an environment of innovation, sharing insights and expertise to further enhance the field of biomedicine.
Conclusion
Shimobi Onuoha's contributions to the fields of immunotherapy and genetic assessment have significantly impacted medical advancements. His numerous patents reflect his commitment to innovation and dedication to improving healthcare solutions. As he continues his work, the potential for new discoveries remains promising, laying the groundwork for future breakthroughs in medical technology.